NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Instruments & Supplies · USD

Sanara MedTech Inc. (SMTI) Stock Analysis

Sanara MedTech Inc. (SMTI) is a Medical Instruments & Supplies stock listed on NASDAQ and quoted in US Dollar.

SMTI

$34.73

+$0.01 (+0.03%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SMTI with… →

SMTI Key Statistics

As of Sep 4, 2026
Trading
Open
$34.62
Previous Close
$34.72
Day's Range
34.62–34.79
52-Week Range
16.05–35.95
Volume
541.70K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.16
Valuation
Market Cap
$319.10M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
64.31
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.91
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.04
Financials (FY)
Revenue (FY)
$103.12M+18.97%
Net Income (FY)
−$37.56M
Profit marginThe share of revenue left as profit after all costs and taxes.
−29.15%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
9.19M
1-Year Return
+2.03%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
233.41K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SMTI Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+48.74%
2025−29.67%
2024−19.22%
2023−9.67%
2022+53.98%
2021−40.78%
2020+209.94%
2019+436.67%
2018−50.00%
2017+50.00%
2016 (partial year)−20.00%

As of September 4, 2026.

SMTI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$103.12M−$37.56M−36.4%
2024$86.67M−$9.66M−11.2%
2023$64.99M−$4.30M−6.6%
2022$45.84M−$7.94M−17.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$103.12M$95.60M$9.15M−$37.56M−36.4%
2024$86.67M$78.53M$1.24M−$9.66M−11.2%
2023$64.99M$57.14M−$7.67M−$4.30M−6.6%
2022$45.84M$39.48M−$12.23M−$7.94M−17.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SMTI Valuation vs Medical Instruments & Supplies Median

Median of 55 stocks
MetricSMTIMedical Instruments & Supplies medianvs median
P/S ratio2.913.178% below
Profit margin−29.15%0.85%30.0 pts below

Medians across 55 Medical Instruments & Supplies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Sanara MedTech Inc. (SMTI) at $319.10M. It is classified in the Medical Instruments & Supplies industry, within the Healthcare sector. Headcount on file is 108.

The 52-week range on file runs from $16.05 to $35.95. The most recent close on file for SMTI is $34.73, dated September 4, 2026. That is +$0.01 (+0.03%) against the previous close. The latest close sits 116.39% above that 52-week low.

Financial Health

In fiscal 2025, Sanara MedTech Inc. reported revenue of $103.12M. Against the prior fiscal year total of $86.67M, that is a change of +18.97%. The same year closed with a net loss of $37.56M. Profit margin runs at −29.15%. That is 30 percentage points below the Medical Instruments & Supplies median of 0.85%. Trailing earnings per share are −0.04.

Across the 4 fiscal years on file, revenue moves from $45.84M in 2022 to $103.12M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 64.31. Measured against sales, the shares trade at 2.91 times revenue. On price-to-sales that is 8.42% below the Medical Instruments & Supplies median of 3.17. The medians here are taken across 55 Medical Instruments & Supplies companies that report the metric.

Beta against the wider market is reported at 1.16. Daily returns over the trailing 10 years annualize to a volatility of 110.59%. The trailing one-year price return is +2.03%. Measured over 10 years, that is +21.39% a year compounded.

Growth & Income

No dividend is on file for SMTI.

Across the complete calendar years on file, 2019 returned +436.67% and 2018 returned −50.00%. Of the 9 complete calendar years on file, 4 finished higher. 2026 is still running; the price is +48.74% year to date.

Peer Comparison

Sanara MedTech Inc. (SMTI) operates in the Medical Instruments & Supplies industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Sanara MedTech Inc. SMTI $319.10M —
Intuitive Surgical, Inc. ISRG $131.38B 42.4
Becton, Dickinson and Company BDX $50.32B 32.0
Medline Inc. MDLN $49.23B 45.7

The Medical Instruments & Supplies industry average P/E ratio is 35.6x. Sanara MedTech Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Instruments & Supplies Stocks

ISRG

Intuitive Surgical, Inc.

$131.38B

 BDX

Becton, Dickinson and Company

$50.32B

 MDLN

Medline Inc.

$49.23B

 ALC

Alcon Inc.

$34.08B

 RMD

ResMed Inc.

$32.94B

 WST

West Pharmaceutical Services, Inc.

$23.93B
View all Medical Instruments & Supplies stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Sanara MedTech Inc.

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Visit website →